Prevalence of Osteoporosis During Long-Term Androgen Deprivation Therapy in Patients with Prostate Cancer

Urology

Volumn 69, Issue 3, 2007, Pages 500-504

  Morote, Juan ^a   Morin, Jacques Planas ^a   Orsola, Anna ^a   Abascal, Jose M ^a   Salvador, Carles ^a   Trilla, Enrique ^a   Raventos, Carles X ^a   Cecchini, Lluis ^a   Encabo, Gloria ^a   Reventos, Jaume ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE;

ADULT; AGED; ANDROGEN THERAPY; ARTICLE; BONE DENSITY; BONE METASTASIS; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR NECK; HUMAN; LONG TERM CARE; LUMBAR SPINAL CORD; MALE; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; ANDROGEN ANTAGONISTS; COMBINED MODALITY THERAPY; COMORBIDITY; CROSS-SECTIONAL STUDIES; DENSITOMETRY, X-RAY; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PREVALENCE; PROSTATECTOMY; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 33947222498     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.11.002     Document Type: Article

References (27)

1. Holzbeierlein J.M., McLaughlin M.D., and Thrasher J.B. Complications of androgen deprivation therapy for prostate cancer. Curr Opin Urol 14 (2004) 177-183
2. Daniell H.W. Osteoporosis after orchiectomy for prostate cancer. J Urol 157 (1997) 439-444
3. Shahinian V.B., Kuo Y.F., Freeman J.L., et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 (2005) 154-164
4. Oefelein M.G., Ricchiuti V., Conrad W., et al. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168 (2002) 1005-1007
5. Amin S., and Felson D.T. Osteoporosis in men. Rheum Dis Clin North Am 27 (2001) 19-47
6. Gilbert S.M., and McKiernan J.M. Epidemiology of male osteoporosis and prostate cancer. Curr Opin Urol 15 (2005) 23-27
7. Pouilles J.M., Tremollieres F., and Ribot C. Variability of vertebral and femoral postmenopausal bone loss: a longitudinal study. Osteoporosis Int 6 (1996) 320-324
8. Smith M.R., McGovern F.J., Zietman A.L., et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 345 (2001) 948-955
9. Smith M.R., Eastham J., Gleason D.M., et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169 (2003) 2008-2012
10. Mittan D., Lee S., Miller E., et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 87 (2002) 3656-3661
11. Maillefert J.F., Sibilia J., Michel F., et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 161 (1999) 1219-1222
12. Higano C.S. Management of bone loss in men with prostate cancer. J Urol 170 (2003) S59-S63
13. Eriksson S., Eriksson A., Stege R., et al. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int 57 (1995) 97-99
14. Diamond T.H., Winters J., Smith A., et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 92 (2001) 1444-1450
15. Diamond T., Campbell J., Bryant C., et al. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 83 (1998) 1561-1566
16. Daniell H.W., Dunn S.R., Ferguson D.W., et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 163 (2000) 181-186
17. Berruti A., Dogliotti L., Terrone C., et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 167 (2002) 2361-2367
18. Morote J., Orsola A., Abascal J., et al. Bone mineral density changes in prostate cancer patients during the first two years of androgen suppression. J Urol 175 (2006) 1679-1683
19. Morote J., Martinez E., Trilla E., et al. Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment. Eur Urol 44 (2003) 661-665
20. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. report of a WHO Study Group. World Health Organ Tech Rep Ser 843 (1994) 1-129
21. Kiratli B.J., Srinivas S., Perkash I., et al. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 57 (2001) 127-132
22. Bruder J.M., Ma J.Z., Basler J.W., et al. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy. Urology 67 (2006) 152-155
23. Miller P.D. Abstracts from the 2005 ISCD Annual Meeting. J Clin Densitom 8 (2005) 228-249
24. Smith M.R., McGovern F.J., Fallon M.A., et al. Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer 91 (2001) 2238-2245
25. Hussain S.A., Weston R., Stephenson R.N., et al. Immediate dual energy x-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int 92 (2003) 690-694
26. Conde F.A., Sarna L., Oka R.K., et al. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Urology 64 (2004) 335-340
27. Wei J.T., Gross M., Jaffe C.A., et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 54 (1999) 607-611